{"nctId":"NCT00557193","briefTitle":"Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia","startDateStruct":{"date":"2008-01-15","type":"ACTUAL"},"conditions":["Acute Lymphoblastic Leukemia","Acute Undifferentiated Leukemia","Childhood T Acute Lymphoblastic Leukemia"],"count":218,"armGroups":[{"label":"Arm A (standard risk MLL-G)","type":"EXPERIMENTAL","interventionNames":["Drug: Asparaginase","Procedure: Biospecimen Collection","Procedure: Bone Marrow Biopsy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Procedure: Echocardiography","Drug: Etoposide","Biological: Filgrastim","Other: Laboratory Biomarker Analysis","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Methylprednisolone","Procedure: Multigated Acquisition Scan","Drug: Pegaspargase","Other: Pharmacological Study","Drug: Prednisone","Drug: Therapeutic Hydrocortisone","Drug: Vincristine Sulfate"]},{"label":"Arm B (IR/HR MLL-R chemotherapy)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Asparaginase","Procedure: Biospecimen Collection","Procedure: Bone Marrow Biopsy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Procedure: Echocardiography","Drug: Etoposide","Biological: Filgrastim","Other: Laboratory Biomarker Analysis","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Methylprednisolone","Procedure: Multigated Acquisition Scan","Drug: Pegaspargase","Other: Pharmacological Study","Drug: Prednisone","Drug: Therapeutic Hydrocortisone","Drug: Vincristine Sulfate"]},{"label":"Arm C (IR/HR MLL-R chemotherapy and lestaurtinib)","type":"EXPERIMENTAL","interventionNames":["Drug: Asparaginase","Procedure: Biospecimen Collection","Procedure: Bone Marrow Biopsy","Drug: Cyclophosphamide","Drug: Cytarabine","Drug: Daunorubicin Hydrochloride","Drug: Dexamethasone","Procedure: Echocardiography","Drug: Etoposide","Biological: Filgrastim","Other: Laboratory Biomarker Analysis","Drug: Lestaurtinib","Drug: Leucovorin Calcium","Drug: Mercaptopurine","Drug: Methotrexate","Drug: Methylprednisolone","Procedure: Multigated Acquisition Scan","Drug: Pegaspargase","Other: Pharmacological Study","Drug: Prednisone","Drug: Therapeutic Hydrocortisone","Drug: Vincristine Sulfate"]}],"interventions":[{"name":"Asparaginase","otherNames":["ASP-1","Asparaginase II","Asparaginase-E.Coli","Colaspase","Elspar","Kidrolase","L-Asnase","L-ASP","L-Asparaginase","L-Asparagine Amidohydrolase","Laspar","Lcf-ASP","Leucogen","Leunase","MK-965","Paronal","Re-82-TAD-15","Serasa","Spectrila"]},{"name":"Biospecimen Collection","otherNames":["Biological Sample Collection","Biospecimen Collected","Specimen Collection"]},{"name":"Bone Marrow Biopsy","otherNames":["Biopsy of Bone Marrow","Biopsy, Bone Marrow"]},{"name":"Cyclophosphamide","otherNames":["(-)-Cyclophosphamide","2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate","Asta B 518","B 518","B-518","B518","Carloxan","Ciclofosfamida","Ciclofosfamide","Cicloxal","Clafen","Claphene","CP monohydrate","CTX","CYCLO-cell","Cycloblastin","Cycloblastine","Cyclophospham","Cyclophosphamid monohydrate","Cyclophosphamide Monohydrate","Cyclophosphamidum","Cyclophosphan","Cyclophosphane","Cyclophosphanum","Cyclostin","Cyclostine","Cytophosphan","Cytophosphane","Cytoxan","Fosfaseron","Genoxal","Genuxal","Ledoxina","Mitoxan","Neosar","Revimmune","Syklofosfamid","WR 138719","WR- 138719","WR-138719","WR138719"]},{"name":"Cytarabine","otherNames":[".beta.-Cytosine arabinoside","1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-.beta.-D-Arabinofuranosylcytosine","1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone","1-Beta-D-arabinofuranosylcytosine","1.beta.-D-Arabinofuranosylcytosine","2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-","2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-","Alexan","Ara-C","ARA-cell","Arabine","Arabinofuranosylcytosine","Arabinosylcytosine","Aracytidine","Aracytin","Aracytine","Beta-Cytosine Arabinoside","CHX-3311","Cytarabinum","Cytarbel","Cytosar","Cytosine Arabinoside","Cytosine-.beta.-arabinoside","Cytosine-beta-arabinoside","Erpalfa","Starasid","Tarabine PFS","U 19920","U-19920","Udicil","WR-28453"]},{"name":"Daunorubicin Hydrochloride","otherNames":["Cerubidin","Cerubidine","Cloridrato de Daunorubicina","Daunoblastin","Daunoblastina","Daunoblastine","Daunomycin Hydrochloride","Daunomycin, hydrochloride","Daunorubicin.HCl","Daunorubicini Hydrochloridum","FI-6339","Ondena","RP-13057","Rubidomycin Hydrochloride","Rubilem"]},{"name":"Dexamethasone","otherNames":["Aacidexam","Adexone","Aknichthol Dexa","Alba-Dex","Alin","Alin Depot","Alin Oftalmico","Amplidermis","Anemul mono","Auricularum","Auxiloson","Baycadron","Baycuten","Baycuten N","Cortidexason","Cortisumman","Decacort","Decadrol","Decadron","Decadron DP","Decalix","Decameth","Decasone R.p.","Dectancyl","Dekacort","Deltafluorene","Deronil","Desamethasone","Desameton","Dexa-Mamallet","Dexa-Rhinosan","Dexa-Scheroson","Dexa-sine","Dexacortal","Dexacortin","Dexafarma","Dexafluorene","Dexalocal","Dexamecortin","Dexameth","Dexamethasone Intensol","Dexamethasonum","Dexamonozon","Dexapos","Dexinoral","Dexone","Dinormon","Dxevo","Fluorodelta","Fortecortin","Gammacorten","Hemady","Hexadecadrol","Hexadrol","LenaDex","Lokalison-F","Loverine","Methylfluorprednisolone","Millicorten","Mymethasone","Orgadrone","Spersadex","TaperDex","Visumetazone","ZoDex"]},{"name":"Echocardiography","otherNames":["EC"]},{"name":"Etoposide","otherNames":["Demethyl Epipodophyllotoxin Ethylidine Glucoside","EPEG","Lastet","Toposar","Vepesid","VP 16","VP 16-213","VP 16213","VP-16","VP-16-213","VP-16213","VP16","VP16213"]},{"name":"Filgrastim","otherNames":["Filgrastim Biosimilar Filgrastim-sndz","Filgrastim Biosimilar Tbo-filgrastim","Filgrastim XM02","Filgrastim-aafi","Filgrastim-ayow","Filgrastim-sndz","G-CSF","Granix","Neupogen","Neutroval","Nivestim","Nivestym","r-metHuG-CSF","Recombinant Methionyl Human Granulocyte Colony Stimulating Factor","Releuko","rG-CSF","Tbo-filgrastim","Tevagrastim","XM02","Zarxio"]},{"name":"Laboratory Biomarker Analysis","otherNames":[]},{"name":"Lestaurtinib","otherNames":["CEP 701","CEP-701","CEP701","KT-5555","SPM-924"]},{"name":"Leucovorin Calcium","otherNames":["Adinepar","Calcifolin","Calcium (6S)-Folinate","Calcium Folinate","Calcium Leucovorin","Calfolex","Calinat","Cehafolin","Citofolin","Citrec","Citrovorum Factor","Cromatonbic Folinico","Dalisol","Disintox","Divical","Ecofol","Emovis","Factor, Citrovorum","Flynoken A","Folaren","Folaxin","FOLI-cell","Foliben","Folidan","Folidar","Folinac","Folinate Calcium","folinic acid","Folinic Acid Calcium Salt Pentahydrate","Folinoral","Folinvit","Foliplus","Folix","Imo","Lederfolat","Lederfolin","Leucosar","leucovorin","Rescufolin","Rescuvolin","Tonofolin","Wellcovorin"]},{"name":"Mercaptopurine","otherNames":["3H-Purine-6-thiol","6 MP","6 Thiohypoxanthine","6 Thiopurine","6-Mercaptopurine","6-Mercaptopurine Monohydrate","6-MP","6-Purinethiol","6-Thiopurine","6-Thioxopurine","6H-Purine-6-thione, 1,7-dihydro- (9CI)","7-Mercapto-1,3,4,6-tetrazaindene","Alti-Mercaptopurine","Azathiopurine","Bw 57-323H","Flocofil","Ismipur","Leukerin","Leupurin","Mercaleukim","Mercaleukin","Mercaptina","Mercaptopurinum","Mercapurin","Mern","NCI-C04886","Puri-Nethol","Purimethol","Purine, 6-mercapto-","Purine-6-thiol (8CI)","Purine-6-thiol, monohydrate","Purinethiol","Purinethol","U-4748","WR-2785"]},{"name":"Methotrexate","otherNames":["Abitrexate","Alpha-Methopterin","Amethopterin","Brimexate","CL 14377","CL-14377","Emtexate","Emthexat","Emthexate","Farmitrexat","Fauldexato","Folex","Folex PFS","Lantarel","Ledertrexate","Lumexon","Maxtrex","Medsatrexate","Metex","Methoblastin","Methotrexate LPF","Methotrexate Methylaminopterin","Methotrexatum","Metotrexato","Metrotex","Mexate","Mexate-AQ","MTX","Novatrex","Rheumatrex","Texate","Tremetex","Trexeron","Trixilem","WR-19039"]},{"name":"Methylprednisolone","otherNames":["Adlone","Caberdelta M","DepMedalone","Depo Moderin","Depo-Nisolone","Duralone","Emmetipi","Esametone","Firmacort","Medlone 21","Medrate","Medrol","Medrol Veriderm","Medrone","Mega-Star","Meprolone","Methylprednisolonum","Metilbetasone Solubile","Metrocort","Metypresol","Metysolon","Predni-M-Tablinen","Prednilen","Radilem","Sieropresol","Solpredone","Summicort","Urbason","Veriderm Medrol","Wyacort"]},{"name":"Multigated Acquisition Scan","otherNames":["Blood Pool Scan","Equilibrium Radionuclide Angiography","Gated Blood Pool Imaging","Gated Heart Pool Scan","MUGA","MUGA Scan","Multi-Gated Acquisition Scan","Radionuclide Ventriculogram Scan","Radionuclide Ventriculography","RNVG","SYMA Scanning","Synchronized Multigated Acquisition Scanning"]},{"name":"Pegaspargase","otherNames":["L-Asparaginase with Polyethylene Glycol","Oncaspar","Oncaspar-IV","PEG-Asparaginase","PEG-L-Asparaginase","PEG-L-Asparaginase (Enzon - Kyowa Hakko)","PEGLA","Polyethylene Glycol L-Asparaginase","Polyethylene Glycol-L-Asparaginase"]},{"name":"Pharmacological Study","otherNames":[]},{"name":"Prednisone","otherNames":[".delta.1-Cortisone","1, 2-Dehydrocortisone","Adasone","Cortancyl","Dacortin","DeCortin","Decortisyl","Decorton","Delta 1-Cortisone","Delta-Dome","Deltacortene","Deltacortisone","Deltadehydrocortisone","Deltasone","Deltison","Deltra","Econosone","Lisacort","Meprosona-F","Metacortandracin","Meticorten","Ofisolona","Orasone","Panafcort","Panasol-S","Paracort","Perrigo Prednisone","PRED","Predicor","Predicorten","Prednicen-M","Prednicort","Prednidib","Prednilonga","Predniment","Prednisone Intensol","Prednisonum","Prednitone","Promifen","Rayos","Servisone","SK-Prednisone"]},{"name":"Therapeutic Hydrocortisone","otherNames":["Aeroseb-HC","Barseb HC","Barseb-HC","Cetacort","Cort-Dome","Cortef","Cortenema","Cortifan","Cortisol","Cortispray","Cortril","Dermacort","Domolene","Eldecort","Hautosone","Heb-Cort","Hydrocortisone","Hydrocortone","Hytone","Komed-HC","Nutracort","Proctocort","Rectoid"]},{"name":"Vincristine Sulfate","otherNames":["Kyocristine","Leurocristine Sulfate","Leurocristine, sulfate","Oncovin","Vincasar","Vincosid","Vincrex","Vincristine, sulfate"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must be enrolled on a Children's Oncology Group (COG) ALL Classification Study (AALL08B1) prior to enrollment on AALL0631\n* Patients must be \\< 366 days of age at the time of diagnosis; for neonates in the first month of life, patients must be \\> 36 weeks gestational age at the time of diagnosis\n* Patients must be newly diagnosed with acute lymphoblastic leukemia (ALL) or acute undifferentiated leukemia (AUL); patients with T-cell ALL are eligible; patients with bilineage or biphenotypic acute leukemia are eligible, provided the morphology and immunophenotype are predominately lymphoid\n* Patients must be previously untreated with the exception of steroids and intrathecal chemotherapy; no other systemic chemotherapy may have been administered; patients receiving prior steroid therapy are eligible for study; any amount of steroid pretreatment will not affect initial induction assignment as long as the patient meets all other eligibility criteria; IT chemotherapy per protocol is allowed for patient convenience at the time of the diagnostic bone marrow or venous line placement to avoid second lumbar puncture; (note: the central nervous system \\[CNS\\] status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy, except for steroid pretreatment); systemic chemotherapy must begin within 72 hours of this IT therapy\n* All patients and/or their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met\n* Patients with mature B-cell ALL or acute myelogenous leukemia (AML) are NOT eligible\n* Patients with Down syndrome are NOT eligible","healthyVolunteers":false,"sex":"ALL","maximumAge":"1 Year","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)","description":"EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2","description":"Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.89","spread":null},{"groupId":"OG001","value":"35.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)","description":"Lestaurtinib-related dose-limiting toxicity proportions, as measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0, will by summarized by dose level for Safety phase patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic AGP Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy","description":"Pharmacokinetic AGP levels in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.","classes":[]},{"type":"SECONDARY","title":"Pharmacokinetic Albumin in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy","description":"Pharmacokinetic albumin in infants given lestaurtinib at DL2 in combination with chemotherapy will be described with mean and standard deviation for those with available data.","classes":[]},{"type":"SECONDARY","title":"Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy","description":"Summarized with mean and standard deviation for those with available data in Arm C","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.00","spread":"22.96"}]}]}]},{"type":"SECONDARY","title":"Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts","description":"Described via mean and standard deviation by group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"2.12"},{"groupId":"OG001","value":"7.85","spread":"10.65"},{"groupId":"OG002","value":"5.83","spread":"5.55"}]}]}]},{"type":"SECONDARY","title":"Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts","description":"Described via means and standard deviations in available Arm C relapse samples","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.73","spread":"4.56"}]}]}]},{"type":"SECONDARY","title":"Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts","description":"Described via means and standard deviations in samples which have primary resistance to lestaurtinib","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.14"},{"groupId":"OG001","value":"0.48","spread":"0.19"},{"groupId":"OG002","value":"0.47","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts","description":"Described via means and standard deviations in samples which have acquired resistance to lestaurtinib","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"0.15"}]}]}]},{"type":"SECONDARY","title":"Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm","description":"Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.05","spread":null},{"groupId":"OG001","value":"87.5","spread":null},{"groupId":"OG002","value":"47.37","spread":null},{"groupId":"OG003","value":"22.73","spread":null},{"groupId":"OG004","value":"51.85","spread":null},{"groupId":"OG005","value":"27.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With Survival Outcomes","description":"EFS outcomes will be reported by genotype.","classes":[]},{"type":"SECONDARY","title":"Identification of Gene Expression Patterns in Diagnostic Infant Leukemia Samples That Correlate With PIA Values","description":"Means and standard deviations of Plasma Inhibitory Activity (PIA) will be given by genotype","classes":[]},{"type":"SECONDARY","title":"Percent Probability for Event-free Survival (EFS) for Patients on Arm A","description":"EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.67","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":210},"commonTop":["Neutrophil count decreased","Infections and infestations - Other, specify","Alanine aminotransferase increased","Febrile neutropenia","Mucositis oral"]}}}